Austin S. Gamblin

Austin S. Gamblin

Auto-generated profile, based on publicly available information

Austin S. Gamblin

School of Medicine, University of Utah, Salt Lake City, Utah, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SBSyeda Maheen Batool
Syeda Maheen Batool
KMKoushik Muralidharan
Koushik Muralidharan
THTiffaney Hsia
Tiffaney Hsia
SFSarah Falotico
Sarah Falotico
AGAustin S. Gamblin
Austin S. Gamblin
BCBob S. Carter
Bob S. Carter
Purpose: Liquid biopsy offers an attractive platform for noninvasive tumor diagnosis, prognostication, and prediction of glioblastoma clinical outcomes. Prior studies report that 30% to 50% of GBM lesions characterized by EGFR amplification also harbor the EGFRvIII mutation. Experimental Design: A novel digital droplet PCR (ddPCR) assay for high GC content amplicons was developed and optimized for sensitive detection of EGFRvIII in tumor tissue and circulating extracellular vesicle RNA (EV RNA) isolated from the plasma of patients with glioma. Results: Our optimized qPCR assay detected EGFRvIII mRNA in 81% [95% confidence interval (CI), 68%–94%] of EGFR-amplified glioma tumor tissue, indicating a higher than previously reported prevalence of EGFRvIII in glioma. Using the optimized ddPCR assay in discovery and blinded validation cohorts, we detected EGFRvIII mutation in 73% (95% CI, 64%–82%) of patients with a specificity of 98% (95% CI, 87%–100%), compared with qPCR tumor tissue analysis. In addition, upon longitudinal monitoring in 4 patients, we report detection of EGFRvIII in the plasma of patients with different clinical outcomes, rising with tumor progression, and decreasing in response to treatment. Conclusions: This study demonstrates the feasibility of detecting EGFRvIII mutation in plasma using a highly sensitive and specific ddPCR assay. We also show a higher than previously reported EGFRvIII prevalence in glioma tumor tissue. Several features of the assay are favorable for clinical implementation for detection and monitoring of EGFRvIII-positive tumors.

14 December 2022 in World Neurosurgery
Verified
Journal Article
Closed access
DCDavide Croci
Davide Croci
SNSarah Nguyen
Sarah Nguyen
SSSeth Streitmatter
Seth Streitmatter
BSBrandon A. Sherrod
Brandon A. Sherrod
JHJeremy Hardy
Jeremy Hardy
ADAndrew T. Dailey
Andrew T. Dailey

15 July 2021 in Cureus
Verified
Journal Article
Open access
AGAustin Gamblin
Austin Gamblin
SNSarah Nguyen
Sarah Nguyen
VFVance Fredrickson
Vance Fredrickson
RGRamesh Grandhi
Ramesh Grandhi
PTPhilipp Taussky
Philipp Taussky
Postoperative digital subtraction angiography (DSA) is the gold standard for establishing a cure of an arteriovenous malformation (AVM) after treatment. The incidence of residual AVM identified on postoperative DSA ranges from 1.8 to 11%. Although this is important for finalizing the treatment of AVMs, postoperative DSA rarely shows new findings that were not previously identified on preoperative imaging. We present a unique case where we identified residual AVM nidus on immediate postoperative DSA that drained into two deep veins that were not evident on preoperative DSA and increased the AVM grade from Spetzler-Martin grade II to III. To our knowledge, this finding has not been previously reported in the literature. We resected the residual AVM nidus identified on postoperative DSA, leading to an angiographic cure. The patient demonstrated a postoperative right-sided supplementary motor area syndrome that resolved over time with therapy. She made a complete functional recovery by her one-month follow-up appointment.

31 March 2023
Verified
Other
Open access
SBSyeda Maheen Batool
Syeda Maheen Batool
KMKoushik Muralidharan
Koushik Muralidharan
THTiffaney Hsia
Tiffaney Hsia
SFSarah Falotico
Sarah Falotico
AGAustin S. Gamblin
Austin S. Gamblin
BCBob S. Carter
Bob S. Carter
Supplementary Data from Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients

31 March 2023
Verified
Other
Open access
SBSyeda Maheen Batool
Syeda Maheen Batool
KMKoushik Muralidharan
Koushik Muralidharan
THTiffaney Hsia
Tiffaney Hsia
SFSarah Falotico
Sarah Falotico
AGAustin S. Gamblin
Austin S. Gamblin
BCBob S. Carter
Bob S. Carter
Supplementary Data from Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients

31 March 2023
Verified
Other
Open access
SBSyeda Maheen Batool
Syeda Maheen Batool
KMKoushik Muralidharan
Koushik Muralidharan
THTiffaney Hsia
Tiffaney Hsia
SFSarah Falotico
Sarah Falotico
AGAustin S. Gamblin
Austin S. Gamblin
BCBob S. Carter
Bob S. Carter
Supplementary Table from Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients